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to investigate the implementation
of the isotretinoin Pregnancy
Prevention Programme: a
descriptive study
Ineke Crijns†, Aukje Mantel-Teeuwisse, Rudi Bloemberg, Eldridge Pinas,
Sabine Straus & Lolkje de Jong-van den Berg
†Medicines Evaluation Board, Utrecht, the Netherlands
Objective: Three online surveys explored compliance with the PPP by pharma-
cists and dermatologists, in the Netherlands. In 2007 and 2011, two pharmacist
surveys were conducted to assess improvement over time.
Methods: In 2007, survey was sent to members of the Utrecht Pharmacy Panel
for Education & Research (UPPER) network (n = 1000) and in 2011, to the
research group of the Dutch Association of Pharmacists (KNMP) (n = 556). In
2010, a survey was sent to 564 dermatologists of the Dutch Association of
Dermatology and Venereology (NVDV).
Results: Both pharmacists’ questionnaires had response rates of 20% and the
dermatologist questionnaire of 28%. Pharmacists’ checks on 30-day dispens-
ing remained 82%, but a check whether the prescription is out-of-date
decreased (61 to 53%). Pharmacists asked the patient for a negative preg-
nancy test in 15%, but use of contraception was checked by 44 -- 49%. One
hundred and five dermatologists (64%) always prescribe contraception;
35 (22%) occasionally. Ninety-three percent of the dermatologists were of
the opinion that they performed the PPP. Analysis of different elements of
the PPP showed that 41 (25%) were compliant.
Conclusions: The observed non-adherence to the isotretinoin PPP calls for care-
ful evaluation of risk minimisation plans and participation of all stakeholders in
the development of these plans.
Keywords: acne, dermatology, isotretinoin, pregnancy, prevention, surveys
Expert Opin. Drug Saf. (2013) 12(1):29-38
1. Introduction
The thalidomide disaster in 1961 -- 1962 revealed that drugs thought to be relatively
safe may disguise a serious risk. This catastrophe increased the awareness of poten-
tial adverse reactions to drug exposure, but also the awareness of pharmacovigilance
during pregnancy or otherwise. Besides developing systems to collect spontaneous
adverse reaction reports due to drug exposure and collecting data for pharmaco-
epidemiology drug utilisation studies, a more pro-active approach on managing
risks has been established, including taking risk minimisation measures, such as a
pregnancy prevention programme [1].
Vitamin A derivates are known to be teratogenic. Isotretinoin, a vitamin A deri-
vative has been licensed for the treatment of acne since 1982 in the USA and
1984 in Europe. Despite the fact that the product information of isotretinoin
(Roaccutane, Roche) contained a contra-indication for pregnancy at the time of
approval, exposure during pregnancy occurred and congenital anomalies have
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been reported, even if isotretinoin had been taken for short
periods of time [2,3]. In 1985, the isotretinoin embryopathy
has been first described by Lammer et al. [4]. This embryop-
athy consists of craniofacial, cardiac, thymic and central ner-
vous system (CNS) defects and has a frequency of 26% in
exposed patients. In 1988, in order to improve the prevention
of pregnancies, Roche introduced a Pregnancy Prevention
Programme (PPP) worldwide [5]. Key principles of the isotret-
inoin PPP are educational material for health care providers
and patients, therapy management and dispensing control.
In 2003, generic formulations of isotretinoin entered the
European market. In the European Union (EU) a review [6]
was performed and the European Commission (EC) decided
that an EU PPP should be applicable to all isotretinoin con-
taining products for systemic use. In addition, the indication
for use was restricted and imposed elements of the PPP were
stricter as well. In the current EU PPP, prescribers, pharma-
cists and patients are involved to perform this PPP appro-
priately. The exact roles are laid down in the product
information and/or educational material [6]. This PPP was
implemented in most EU countries [7]. See Box 1 for all
elements of the current EU PPP.
Pro-active risk minimisation programmes such as the iso-
tretinoin PPP have been developed to prevent undue harm
to patients. Effectiveness in reducing risks by measures itself
such as the individual elements of these programmes is hardly
performed. Studies on the effectiveness of the PPP as a whole
indicate that the programme lacks complete effectiveness
because pregnancies still occur both in the USA [8] and
Europe [9]. Effectiveness of risk minimisation programmes
in daily medical practice largely depends on actual compliance
with these programmes by the stakeholders. Patients’ compli-
ance has been assessed with regard to adherence of contracep-
tion requirements in several studies [10-12]. These studies
showed that not all women of childbearing potential receiving
isotretinoin use one contraceptive method not to mention two
methods. Limited information, however, is available on com-
pliance with the current isotretinoin PPP recommendations
by pharmacists [13,14] and dermatologists [13]. Therefore, we
conducted three surveys among health care professionals
and the aim of these surveys was to explore the compliance
with the isotretinoin PPP by community pharmacists and
dermatologists in the Netherlands. The two surveys among
pharmacists have been conducted in 2007 and 2011, allowing
us to assess improvements over time. The second pharmacist
survey and the dermatologist survey (2010) are part of an
investigational programme because of the results of the first
pharmacist survey.
2. Materials and methods
2.1 Data collection
Three surveys were performed, two among pharmacists and
one among dermatologists.
2.1.1 UPPER network
In 2007, a short online questionnaire was developed for a pilot
study and the link was sent once (April 16, 2007) to approxi-
mately 1000 community pharmacies who are member of the
Utrecht Pharmacy Panel for Education & Research (UPPER)
network of the Department of Pharmaceutical Sciences,
Utrecht University, the Netherlands. Pharmacists participating
in the UPPER network are practising pharmacists. The ques-
tionnaire was closed after 2 weeks, because the number of com-
pleted questionnaires was higher than anticipated for this pilot
study. The structured questionnaire contained a combination
of 14 closed and open questions. The questions addressed apart
from general issues, more specific items as checks on dispens-
ing, therapy management, perceived responsibility and role of
the pharmacist. Demographic characteristics were not collected
for this pilot study.
Responders to this survey could provide their e-mail
address for information about the outcome of the study.
Forty-five percent of the responders did so and these e-mail
addresses were all different, indicating that one pharmacist
per pharmacy responded.
2.1.2 Dutch association of pharmacists
In 2011, it was decided to repeat the 2007 survey among
pharmacists and the questionnaire was amended based on
the questionnaire of the UPPER network and consisted of
22 questions. The link to this questionnaire was originally
included in a Newsletter of the Dutch Association of Pharma-
cists, but because of a low response, the link to the question-
naire was sent in addition to the specific research group of the
Association (n = 556 practising pharmacists) by e-mail on
Box 1. Elements of the current EU PPP.
Contraindication pregnant women and women of childbearing potential unless all the conditions of the PPP are met
Medically supervised pregnancy tests before, during and after discontinuation




Patient information on contraceptive methods
Informed consent form
Restricted supply females of childbearing potential, for 30 days and prescription validity of 7 days
I. Crijns et al.



























































April 1, 2011. After three weeks a reminder was sent. The
collection period covered a 3-month period from 1 April
2011 through 1 July 2011.
2.1.3 Dermatologists
In 2010, a questionnaire was developed consisting of eight
questions aimed at dermatologists. An e-mail with a link to
this questionnaire was sent to 564 practicing dermatologists
and dermatologists in training registered with the Dutch
Association of Dermatology and Venereology (NVDV).
A reminder was sent once, after six weeks. The response was
collected over the period of May 2010 through September
2010. The questions concerned those parts in the PPP dealing
with information provision to patients, actions of prescribers
and their interaction with patients.
2.2 Compliance definitions
Full compliance with the isotretinoin PPP for pharmacists
consists of adherence to dispensing control (dispensing for
30 days, prescription validity of 7 days), provision of educa-
tional material and check of availability of negative pregnancy
testing and use of contraception at time of every dispensing of
isotretinoin to women of childbearing potential.
For dermatologists, full compliance with the PPP consists
of providing information on the PPP, prescribing contra-
ceptive measures, performing monthly pregnancy tests and
prescribing isotretinoin for a maximum of 30 days.
2.3 Analyses
Duplicates and incomplete questionnaires were excluded from
the analyses. Incomplete questionnaires were defined as ques-
tionnaires of which the completion was interrupted and there-
fore were not filled in up to the end. Questionnaires in which
some questions were not answered were included, which was
defined as missing in the analyses.
Descriptive statistics were performed on the data collected
by the questionnaires.
3. Results
3.1 Pharmacist questionnaires 2007 and 2011
3.1.1 General
A total of 208 pharmacists participated in the 2007 survey, a
response rate of 20%. In most of the pharmacies (69%) less
than five patients filled prescriptions for isotretinoin at time
of the survey.
A total of 155 questionnaires were filled in the 3-month
period in 2011. Eliminating duplicates and incomplete
filled responses, 148 questionnaires were included in the
analyses consisting of reactions on the Newsletter and
the Association research group. Only the response rate of
the research group could be determined, because the source
population of the Newsletter could not be determined.
The response rate of the research group was 20%, 109 out
of 556 pharmacists.
In 2011, of the responding pharmacists 61% (n = 90) were
female and 39% (n = 58) were male pharmacists. Thirty-nine
percent of all pharmacists (n = 57) belonged to the age group
of 23 -- 35 years of age, 29% (n = 43) to the age group 35 --
45 years of age, 23% (n = 34) to the age group 45 -- 55 years
of age and 9% (n = 14) to the age group 55 -- 65 years of age.
Hundred forty-three (97%) pharmacists were working in a
community pharmacy. About half of the responders, 51%
(n = 76), had less than 5 patients filling prescriptions
for isotretinoin.
In 2007, 78% of the pharmacists confirmed that they were
aware of the isotretinoin PPP compared with 96% of the
responders in 2011, see Table 1.
Results reported below are also presented in Table 1.
3.1.2 Distribution control
Approximately one-third of all pharmacists (32 -- 34%)
accepted prescriptions from dermatologists only. Most phar-
macists (90% in 2007, 84% in 2011) dispensed generic forms
of isotretinoin only.
In both surveys the 82 -- 83% of the pharmacists indicated
that they receive a computer alert reminding them that the
prescription of isotretinoin should be limited to a 30-day sup-
ply for all female patients at risk of pregnancy. Only 35%
never deviated from this rule. Main reasons mentioned for
deviation from the requirement were prescriptions for male
patients, patient’s holidays, on request of the prescriber
or unintended ignorance of the computer alert. The 7-day
validity of the isotretinoin prescriptions was adhered to by
61% in 2007 compared to 53% in 2011.
Only 15 -- 16% of the pharmacists mentioned asking for a
negative pregnancy test result before each dispensing of isotreti-
noin to women of childbearing potential, whereas more than
half of the pharmacists stated that they never asked for test
results. The use of contraception was checked at time of every
dispensing by 44 -- 49%, at time of first dispensing only by
20.7% in 2007, but by 33.8% of the pharmacists in 2011.
3.1.3 Information provision
Both surveys reported that approximately 10 -- 14% did not
provide any information on the isotretinoin PPP to women
of child bearing potential. Information on contraception was
more frequently provided in 2011 than in 2007 (72.3% and
38.9%, respectively).
3.1.4 Responsibility
With both surveys, the majority of pharmacists (72 -- 74%)
considered that the main responsibility for the isotretinoin
PPP lies with the prescribers. Others considered a combina-
tion of prescriber and either pharmacist or patient or all of
them primarily responsible for the programme. On the other
hand, 63.5% of the pharmacists in 2007 agreed they should
play a role in monitoring the isotretinoin PPP in the surveil-
lance or otherwise, which was even higher in 2011 (82.4%),
although 12.8% added objections.
Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme



























































Table 1. Results on responses by both pharmacists’ surveys and the dermatologist survey.
UPPER
Network 2007
n = 208 (%)
Dutch Association
of Pharmacists 2011
n = 148 (%)
Dermatologists
2010
n = 161 (%)
General
Number of patients on isotretinoin at time of the survey
< 5 143 (68.8) 76 (51.4)
5 -- 10 50 (24.0) 54 (36.5)
11 -- 20 12 (5.8) 12 (8.1)
> 20 3 (1.4) 6 (4.1)
Are you aware of a Pregnancy Prevention Programme for isotretinoin?
Yes 163 (78.3) 142 (95.9) 152 (94,4)
No 18 (8.7) 6 (4.1) 9 (5.6)
Missing 27 (13.0)
Distribution control
From which prescribers do you accept a prescription for isotretinoin?
Dermatologist 70 (33.7) 48 (32.4)
Dermatologists, GP and/or gynaecologist 44 (21.6) 42 (28.4)
All physicians 86 (41.3) 58 (39.2)
Does your pharmacy system provide an alert on the maximum of 30 days per prescription?
Yes 172 (82.7) 121 (81.8)
No 25 (12.0) 27 (18.2)
Missing 11 (5.3)
Do you deviate from this rule?z
Never 71 (34.1) 53 (35.8) 80 (49.7)
Rarely 38 (18.3) 46 (31.1) 61 (37.9)
Regularly 37 (17.8) 6 (4.1)
Only in exceptional circumstances 43 (20.7) 42 (28.4)
Missing 19 (9.1) 1 (0.7) 3 (1.9)
Do you check the validity of 7 days for a prescription of isotretinoin?
Yes 127 (61.1) 79 (53.4)
No 66 (31.7) 25 (16.9)
Only in exceptional circumstances 44 (29.7)
Missing 15 (7.2)
Providing information
To whom do you provide information regarding the PPP of isotretinoin?
All patients 45 (21.6) 34 (23.0)
Women of childbearing potential 121 (58.2) 91 (61.5)
Others 9 (4.3) 2 (1.4)
No additional information will be provided 22 (10.6) 21 (14.2)
Missing 11 (5.3)
Which brochures will be provided?
On isotretinoin
Yes 163 (78.4) 127 (85.8)
No 45 (21.6) 21 (14.2)
On contraceptive methods
Yes 81 (38.9) 107 (72.3)
No 127 (61.1) 41 (27.7)
Other information
Yes 3 (1.5) 107 (72.3)
No 205 (98.5) 41 (27.7)
Additional oral information?
Yes 120 (57.7) 108 (73.0)
*Contraception will be prescribed by 105 responders (65%), but including those who first check before prescribing or refer patients to a gynaecologist or GP it
will be 140 responders (87%).
zDermatologist had the option to answer ‘always’ (n = 17), which is not covered by the options presented.
§12.8% of these pharmacists added objections.
NA: Not Applicable.
I. Crijns et al.



























































3.1.5 Compliance with the PPP (not in Table 1)
In both surveys, only a limited number of pharmacists, 6.7%
in 2007 and 8.8% in 2011, fully complied with all aspects of
the isotretinoin PPP. Pharmacists complying with all aspects
of the dispensing control element that is part of the isotreti-
noin PPP as stated in the methods section consisted of 39%
in both groups.
In 2011, pharmacists were asked for suggestions to increase
the compliance with the PPP. Suggestions received were:
oblige prescriber to prescribe contraceptives together with
drugs like isotretinoin, better communication, better informa-
tion tools, informed consent form for patients to be signed at
the pharmacy, to improve the pharmacy monitoring systems,
to have stickers with warnings for drugs like isotretinoin and
unambiguous policy on responsibility of the individual
stakeholders of such programmes.
3.2 Dermatologists
3.2.1 General
Hundred-sixty one out of the 564 surveyed dermatologists and
dermatologists in training completed the questionnaire, a response
rate of 28.5%. Results reported below are presented in Table 1.
Responders were aware of the PPP of isotretinoin through
their professional association in 35%, followed by the phar-
maceutical industry (12%), literature (4%) or the product
information of isotretinoin (2%). Most of the responders
received the information through a combination of the differ-
ent sources (41%). Nine dermatologists (6%) indicated not to
be aware of the PPP.
3.2.2 Providing information
Time needed to inform the patient and performing the other
PPP elements for prescribers took the responders mostly
Table 1. Results on responses by both pharmacists’ surveys and the dermatologist survey (continued).
UPPER
Network 2007
n = 208 (%)
Dutch Association
of Pharmacists 2011
n = 148 (%)
Dermatologists
2010
n = 161 (%)
No 29 (13.9) 39 (26.4)
Missing 59 (28.4) 1 (0.7)
Responsibility
Who is responsible for the PPP?
Prescriber 150 (72.1) 110 (74.3) 4 (2.5)
Specific arrangements 11 (7.3) 10 (6.8)
No specific arrangements 139 (92.7) 100 (67.6)
Pharmacist 9 (4.3) 9 (6.1)
Patient 10 (4.8) 11 (7.4) 40 (24.8)
Otherwise 25 (12.0) 18 (12.2)
Combination prescriber and pharmacist 14 (56.0) 10 (55.6) NA
Combination prescriber and patient 4 (16.0) 2 (9.0) 117 (72.7)
Combination prescriber, pharmacists and patient 6 (24.0) 6 (33.3) NA
Regulatory authority and pharmaceutical industry 1 (4.0) NA
Missing 14 (6.7)
Compliance with the PPP
Do you check the following?
Negative pregnancy test
First dispensing/prescription 27 (13.0) 32 (21.6) 145 (90.0)
Each dispensing/prescription 32 (15.4) 23 (15.5) 104 (64.6)
Never 106 (51.0) 92 (62.2) 12 (7.5)
Missing 43 (20.7) 1 (0.7) 3 (1.9)
Contraceptive use
First dispensing/prescription 43 (20.7) 50 (33.8) 105 (65.2)/140 (87.0)*
Each dispensing/prescription 91 (43.8) 72 (48.6)
Never 41 (19.7) 26 (17.6)
Missing 33 (15.9)
Has the pharmacist a controlling function regarding the PPP?
Yes 132 (63.5) 122 (82.4)§
No 56 (26.9) 26 (17.6)
Missing 20 (9.6) 19 (12.8) ‘otherwise’
*Contraception will be prescribed by 105 responders (65%), but including those who first check before prescribing or refer patients to a gynaecologist or GP it
will be 140 responders (87%).
zDermatologist had the option to answer ‘always’ (n = 17), which is not covered by the options presented.
§12.8% of these pharmacists added objections.
NA: Not Applicable.
Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme



























































5 min (35%), or less (34%). Three responders mentioned that
either a nurse or a physician assistant performed these tasks.
3.2.3 Responsibility
According to 117 responders (72.7%), the responsibility for
pregnancy prevention should be a shared responsibility by
both prescriber and patient. Forty responders (24.8%) consid-
ered the patient solely responsible for the adherence to the
PPP. Four responders considered it completely their responsi-
bility (2.5%).
Furthermore, 10 responders (6.2%) informed the patient
about the risks but stated that pregnancy prevention was the
patient’s responsibility.
3.2.4 Compliance with the PPP
Hundred-five responders (65%) also prescribed contracep-
tives. In addition, 35 dermatologists (22%) mentioned that
they prescribed contraceptives after checking whether the
patient is already on contraception or refer patients to a
gynaecologist or general practitioner for contraception. Ten
responders (6.2%) mentioned that they would not prescribe
a contraceptive for patients indicating to be not sexually
active, for instance in case of religious reasons.
Ninety-three percent of the dermatologists were of the
opinion he/she adhered to the PPP, see Table 2. Breaking
down the PPP to the specific elements for dermatologists, it
seemed that only 41 (25%) of the responders adhered to the
PPP. Of the 115 responders who agreed on the current
PPP, 34 (29.5%) adhered to all elements of the PPP. But
7 of the 46 responders (15.6%) not in agreement on the
current PPP or the need of a PPP, adhered to the PPP (not
in Table 2 as will be also the following results).
Forty-five responders (28%) experienced no problems with
adherence to the PPP. Problems on adherence to the PPP
were reported by 72% responders. Patient related problems
were for instance refusal to use contraceptives due to religion.
A concern mentioned by dermatologists was possible under
treatment of patients due to refusal of isotretinoin because
of the PPP.
3.2.5 Proposals for change or improvement
Hundred-fifteen (71%) of the responders agreed with the
need for a PPP for isotretinoin. Reasons for disagreement
were that the PPP were unnecessary (n = 6), no difference
compared to other products with a contraindication for
use during pregnancy (n = 6), responsibility of the patient
after providing information (n = 5). The other reasons
addressed discontent instead of disagreement too strict
(n = 10), patronising (n = 9), time consuming (n = 2) and
single arguments such as it will cause concerns, cause an
unnecessary threshold, there is no 100% guarantee, too
interfering, too many exceptions and too general.
Proposals for change or improvement of the PPP by the
physicians were given by 75 (47%) of the responders. Pro-
posals ranged from abolition of the PPP to have a more clear
information package. Changes proposed more than once
were:
. The prevention of pregnancy is only patients’
responsibility
. To extend the prescription and control intervals
. To execute the PPP based on judgment of the situation
. To abolish the mandatory pregnancy tests
. To have a patient contract by which it is clear that
pregnancy prevention is the responsibility of the patient
. To have a guideline/advice instead of the obliga-
tion, which can also be used for other drugs with a
contraindication for pregnancy
Other proposals were for instance to have GPs or nurses
performing the monthly controls, return to the old less
restricted PPP, discarding of the informed consent form,
exclude the actions for the pharmacist (control of the
restricted prescription for 30 days, and delivery within
7 days of the date of prescription).
4. Discussion
According to the majority of Dutch community pharmacists
as well as dermatologists, the main responsibility for the
isotretinoin PPP should be either with the prescribers or a
joint responsibility of prescriber and patient. In general, com-
munity pharmacists acknowledge their role of monitoring the
isotretinoin PPP; however, the programme requirements are
not fully adhered to in daily medical practice. Only two out
of five pharmacists adhered to all requirements concerning









Execution PPP as entirety 150 (93) -- (0) 8 (5) 3 (2)
Separate elements
Signing informed consent form 112 (70) 31 (19) 15 (9) 3 (2)
Performance of pregnancy tests 104 (65) 41 (25) 12 (7) 4 (2)
Monthly prescriptions 79 (49) 61 (38) 16 (10) 5 (3)
Regular prescriptions contraceptive 82 (51) 65 (40) 10 (6) 4 (2)
I. Crijns et al.



























































dispensing control, and < 10% reported full compliance with
all the elements of the isotretinoin PPP. Adherence of the
pharmacists was especially poor in terms of supervision of
use of contraception and check of negative pregnancy
test results. And adherence did not improve over time
even though the PPP has been brought to the attention of
pharmacists during this period.
Adherence to the PPP seemed somewhat better by derma-
tologists. However, monthly prescriptions and prescribing of
contraceptives were poor. The dermatologists considered
themselves more responsible for the execution of the PPP
than the pharmacists. Prescribers were more alert regarding
pregnancy tests and contraceptive use.
The response rates to the questionnaires are a limitation of
the study. It is possible that only motivated health care profes-
sionals responded. If so, our results may present a more positive
view about the adherence to the PPP. However, response rates
of online surveys among pharmacists and physicians might
range from 3.1% [15,16] to 75% [17,18], but are mostly between
30 -- 40%. A recent publication [19] shows that response rates
to web-based questionnaires are becoming comparable to those
responding to traditional modes of data collection. Therefore,
mode of distribution of the questionnaire might not be the
reason for this response rate.
Community pharmacists who belong to the UPPER
network of Utrecht University and the research group
of the Dutch Association of Pharmacists may represent a
selected group of pharmacists as they belong to these
groups because of their interest in pharmaceutical practice
research and/or because they offer internships to pharmacy
students. However, both groups consist merely of com-
munity pharmacists and were recruited in a similar way.
The instructions for completion of the questionnaire circu-
lated to pharmacies of the UPPER network did not contain
instructions for completion (on behalf the pharmacy or
personal opinion), which could be regarded as a limitation.
Another limitation of the present study is that responses
to questions in the surveys could not be validated. As a con-
sequence, all results reflect pharmacists’ or dermatologists’
self-reported behaviour. It can therefore not be ruled out
that performance of Dutch community pharmacies and
dermatologists in general may even be more disappointing.
For instance, almost all (93%) of the responding dermato-
logists thought they adhered to the PPP, but taking into
account individual elements of the PPP for prescribers,
only a quarter adhered to the PPP as stated in the product
information. A limitation is also the omission in the
dermatologists’ survey to have pharmacists as an option for
having a responsibility for the PPP.
Evaluation of implementation of risk minimisation pro-
grammes in daily practice is important, because weaknesses
might be revealed and could be corrected. Medical literature
on this subject is scarce, whereas knowledge on implementa-
tion and effectiveness of risk minimisation programmes
is essential to achieve full benefits from these programmes.
Regulatory authorities may learn from the gaps identified in
the present study for future programmes.
No information is available on adherence to the dispensing
control element (restriction to 30-day supply and 7-day
validity) of the isotretinoin PPP in the Netherlands or in other
European countries. Boucher et al. [20] reported that Canadian
pharmacists had given verbal information about teratogenicity
and pregnancy prevention to 78% of the women participating
in their survey. In addition, pharmacists gave written infor-
mation other than the package insert to 62% of the women
filling their isotretinoin prescription. These results are similar
to the results presented in this study. Although our pharmacist
surveys did not focus on the physician’s role in adherence
to the programme, several pharmacists reported that they
filled prescriptions that were not limited to 30 days of treat-
ment at physicians’ request. In addition, several pharmacists
reported that patients presented undated prescriptions.
Regretfully, the performance of the PPP by pharmacists did
not improve over the years based on the results of both our
pharmacists’ surveys.
Previous studies showed that the physician’s adherence
to the isotretinoin PPP should be improved. A retrospective
cohort study [21] assessing documentation of use of contra-
ception or recent contraceptive counselling in the USA
in 2001, the year before institution of the SMART risk
management programme, showed that documentation
was available in only 62% of isotretinoin prescriptions
filled. A more recent US study [22] showed that 9% of
qualified prescriptions as part of the SMART programme
were issued without a pregnancy test. In addition, a cross-
sectional Canadian survey [21] showed that pregnancy testing
was poor before and during (every month of) isotretinoin
use (44% and 13%, respectively). In this survey, a direct
relationship between counselling and recommendations
given by physicians and women’s use of two forms of birth
control was established.
Our study suggests that risk management programmes
may be supported with provision of educational material to
healthcare professionals. Physicians prescribing isotretinoin
for the first time and new pharmacists should therefore also
be informed about the isotretinoin PPP. Our data suggest
that new physicians prescribing isotretinoin may include
others than dermatologists alone, and therefore provision
of information should not be limited to dermatologists.
Enduring awareness of the PPP recommendations and their
underlying principles should be maintained among healthcare
professionals, and for pharmacies computer alerts seem a
helpful tool to achieve this awareness.
One of the interesting results of the present surveys among
Dutch community pharmacists and dermatologists is the
acknowledgement of their own role in conducting the isotreti-
noin PPP. At the same time the fact that pharmacists attribute
the main responsibility for the compliance with the pro-
gramme to the treating physicians. This is confirmed by the
dermatologists who acknowledged their responsibility alone
Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme



























































or sharing it with the patient. This finding may explain why
only a minority of pharmacists (15.4%) reported that they
asked for pregnancy test results before every dispensing
of isotretinoin to fertile women. Responsibilities are not
explicitly laid down in the current isotretinoin PPP and this
might be a key issue in the development of new PPPs by the
regulatory authorities.
A more proactive approach towards the identification and
quantification of safety concerns after marketing has been
implemented in the EU in November 2005 by the obligatory
submission of an EU Risk Management Plan (EU-RMP).
Part of the RMP should evaluate the need for risk minimisa-
tion activities and, if considered needed, a description of these
activities. Proposals for risk minimisation activities other than
pregnancy prevention programmes, for example, monitoring
of laboratory measurements, may also require specific physi-
cians’ and pharmacists’ achievements and behaviour. The
observed non-adherence to the isotretinoin PPP calls for care-
ful evaluation of proposed risk minimisation plans and
participation of all stakeholders in the developmental phase
of these plans.
5. Conclusion
According to the majority of Dutch community pharmacists as
well as dermatologists, the main responsibility for the isotreti-
noin PPP should be either with the prescribers or a joint
responsibility of prescriber and patient. Although pharmacists
acknowledge their role in monitoring the isotretinoin PPP,
requirements of this programme are adhered to a limited extent
in daily pharmaceutical practice. Dermatologists’ actual adher-
ence to the elements of the PPP is inadequate. Pharmacists and
prescribers could enhance the compliance with the PPP by
working together and so complementing each other. Prescribers
consider female patients responsible for preventing pregnancy
and therefore they should provide the conditions to ensure
the highest possible compliance by the patients. These findings
are important in view of future programs. Reinforcement of the
current isotretinoin PPP is warranted.
6. Expert opinion
According to dermatologists, oral isotretinoin is the most
effective drug to treat acne. Therefore, despite its high risk
of human teratogenicity by a treatment indication which is
not life-threatening there is a need for this drug. This high
risk of human teratogenicity is a burden for the pharma-
ceutical company and regulatory authorities, which has lead
to successive PPPs.
Ultimately, effectiveness of the isotretinoin PPP should be
reflected in decreasing numbers of pregnancies exposed to
isotretinoin. A systematic literature review [23] on studies
regarding the implementation and adherence to the isotreti-
noin PPP showed that few studies were performed in Europe.
Successively performed studies in France on data collected
over the period 1987 up to and including 2006 showed that
despite strengthening of the programme, the pregnancy rate
did not change. All identified studies evaluated the compli-
ance with the PPP of isotretinoin in their respective countries.
A common conclusion of all studies/surveys was that the com-
pliance was regarded insufficient and that the PPP should be
strengthened. The case reports indicate that pregnancies
occurred despite a PPP for isotretinoin was adhered to. In
the USA, similar results are seen; evaluation [24] of the
SMART programme showed that pregnancy rate for patients
participating in the pharmacy compliance survey was compa-
rable to that reported before this programme. Evaluation [8] of
the even stricter programme iPLEDGE showed a similar
pregnancy rate as with the previous SMART programme.
Reinforcement of the present isotretinoin PPP, however,
seems warranted and should involve all stakeholders including
pharmaceutical companies, regulatory authorities, physicians,
pharmacists and patients.
Investigations to the effectiveness of the PPP for other
products, such as thalidomide and lenalidomide, have been
done by the pharmaceutical company itself. These studies
focused on the occurrence of pregnancies, but also on the
adherence to the programme by healthcare professionals and/
of patients. It has been suggested that medical specialists
would have a better adherence to the PPP than general practi-
tioners. However, in a drug utilisation study [12] on isotretinoin
it was indicated that general practitioners had a better
performance.
A recent survey conducted among dermatologists in Saudi
Arabia [25] showed also that some dermatologists are not com-
pliant with recommendations for isotretinoin use in women
of childbearing potential. This study is one of the few studies
performed among dermatologists and the actual adherence to
the PPP.
Based on our study, information of the performance by the
actual executioners of risk minimisation measures is collected.
This information indicates that some aspects of the execution,
mainly concerning personal feelings and views can stand
in the way of proper performance or full adherence of
these measures.
In principle, the PPP fails with every pregnancy exposure
occurring. Based on studies performed on the isotretinoin
PPP other possible failures were: no 100% contraceptive use
in female isotretinoin users; the majority of dermatologists
do not perform all the tasks of the PPP; and the majority of
pharmacists also lack adherence to their tasks of the PPP.
Regarding the latter, pharmacists and prescribers could
enhance the compliance with the PPP by working together
and so complementing each other.
The studies and surveys on the isotretinoin PPP seem to
point in the direction of the patient and the possible insuffi-
cient compliance with contraception. This might be obvious,
because that is the end of the chain before getting pregnant.
However, the PPP should be a shared responsibility and
conditions to be compliant with contraception, preventing
I. Crijns et al.



























































pregnancy, should be provided by all stakeholders including
authorities, prescribers, pharmacist and patients.
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